We provide a vast library of targeting ligands, including high-affinity monoclonal antibodies (mAbs), single-chain variable fragments (scFvs), and RNA/DNA aptamers. These ligands are engineered to target classic CSC markers such as CD44, CD133, ALDH, and EpCAM, as well as emerging targets like Lgr5 and CD24.
Learn More →Cancer Stem Cell targeted Antibody modified Nanoparticle Development Service
Creative Biolabs provides an end-to-end solution for addressing the "root cause" of tumor malignancy. By specifically targeting the cancer stem cell (CSC) subpopulation, our service helps researchers bypass the primary limitations of non-selective systemic therapy, such as dose-limiting toxicity and poor penetration into the quiescent tumor core. We offer a sophisticated platform that transforms traditional payloads into "smart" therapeutic systems capable of identifying and eliminating cells expressing stemness markers.
Background What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Introduction to CSC-Targeted Nanoparticle Mechanisms
CSCs represent a highly resilient subpopulation characterized by self-renewal and multi-lineage differentiation capabilities. These cells are the primary drivers of tumor recurrence due to their ability to remain quiescent and overexpress adenosine triphosphate-binding cassette (ABC) efflux transporters, which effectively purge traditional chemotherapeutic agents from the cytoplasm. Recent literature supports the use of antibody-modified nanoparticles as a "smart" delivery platform that leverages specific biomarkers like CD44 and CD133 to bypass these resistance mechanisms. By integrating on-demand release strategies and multimodal therapy, these targeted systems offer a scientifically validated path toward achieving total tumor clearance.
Tailored Solutions for CSC Eradication
Creative Biolabs offers a modular and highly customizable service suite designed to address the multifaceted nature of cancer stemness. Our offerings are categorized into three core technical pillars:
High-Affinity Targeting Modules
Stimulus-Responsive Nanocarriers
Our platform includes the development of "environment-aware" carriers. We offer pH-sensitive polymers that disassemble in the acidic tumor interstitium, redox-responsive shells that respond to high intracellular glutathione levels, and hypoxia-activated systems designed to release payloads specifically within the oxygen-deprived CSC sanctuary.
Learn More →Synergistic Co-delivery Systems
We specialize in the simultaneous encapsulation of diverse therapeutic agents. Our "prime and strike" strategy allows for the co-delivery of a CSC-sensitizer (e.g., a Notch or Wnt inhibitor) alongside a potent cytotoxic agent, ensuring that the stem-like population is sensitized to therapy before the lethal dose is released.
Learn More →Discover How Our Precision Engineering Can Elevate Your Research - Request a Technical Consultation
Workflow
The development process is designed for maximum transparency and scientific rigor, ensuring that every batch of nanoparticles meets your specific research requirements.
Publication
This review explores the critical challenge of CSCs, which drive tumor recurrence and drug resistance. It details how advanced nanocarriers, functionalized with targeting ligands, can specifically deliver therapeutic agents to CSCs. The article comprehensively covers various nanomaterial strategies, including drug delivery, CRISPR/Cas9, exosomes, and nanoparticle-mediated ablation therapies, aimed at overcoming therapeutic resistance and eradicating CSCs to improve cancer treatment outcomes.
Fig.1 Schematic of targeted nanocarriers binding to tumor cell receptors for localized drug delivery. 1
Why Choose Us?
Creative Biolabs offers unparalleled technical depth to overcome cancer stemness and ABC efflux transporters. We utilize site-specific antibody conjugation to bypass P-glycoprotein-mediated resistance, achieving superior cellular uptake. Our platform leverages programmed release kinetics for a "pre-sensitization" phase, releasing differentiation-inducing agents before cytotoxic cargo to shift CSCs into a vulnerable state. Validated with patient-derived organoids, our approach optimizes nanocarriers for the complex tumor microenvironment, ensuring total tumor eradication and bridging the gap between research and clinical success.
Experience the Creative Biolabs Advantage — Get a Detailed Quote Today
FAQs
What type of antibodies can be used for targeting?
We can conjugate full-length IgGs, scFv fragments, or F(ab')2 fragments. We also offer aptamer and peptide conjugation if your research requires a smaller ligand footprint for deeper tissue penetration.
Can you deliver multiple drugs in a single nanoparticle?
Yes, our programmed co-delivery systems allow for the encapsulation of both a sensitizing agent (to disrupt CSC dormancy) and a lethal chemotherapeutic, often released in a precise, sequential manner.
How do you ensure the nanoparticles do not target normal stem cells?
We utilize dual-targeting strategies and logic-gated activation (e.g., pH-triggering) so that the payload is only released in the acidic, hypoxic tumor microenvironment, significantly reducing off-target effects.
Customer Review
-
Enhanced Niche Penetration
Using Creative Biolabs' pH-responsive nanoparticles in our research has significantly facilitated the delivery of Salinomycin into the hypoxic core of pancreatic tumors, overcoming the usual solubility issues. - Dr. Al***n M -
Superior Targeting Specificity
The CD133-targeted aptamer-modified NPs we developed with this team showed a 10-fold increase in uptake in our liver CSC models compared to non-targeted versions. The stability of the conjugate was impressive. - Prof. Sa***ah K
Related Services
Cancer Stem Cell Wnt/Notch/Hedgehog Pathway Inhibitor Validation
Creative Biolabs validates inhibitors targeting Wnt, Notch, and Hedgehog pathways to ablate resistant CSCs. Using multi-omics and 3D modeling, we ensure preclinical success against metastasis and relapse.
Learn More →Engineering Cancer Cells via Genetic Methods
Creative Biolabs offers cancer gene therapy services, engineering viral and non-viral vectors to deliver therapeutic nucleic acids. We ensure high efficiency and safety to precisely destroy tumor cells and prevent relapse.
Learn More →How to Contact Creative Biolabs
With over two decades of experience and a finger on the pulse of the latest breakthroughs, Creative Biolabs is uniquely positioned to accelerate your oncology pipeline. Our services transform your therapeutic concept into a potent, CSC-eradicating candidate.
For more information, please visit our inquiry page or email our scientific support team directly to discuss your specific research goals.
Reference
- Kumbhakar, D. V., et al. "Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence." Front Oncol 15 (2025): 1499283. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fonc.2025.1499283
Download our brochureLoading case studies...
Online Inquiry